Isaac Ciechanover Unloaded $680,534 Worth of Atara Biotherapeutics, Inc. (ATRA) Shares; 8 Bullish Analysts Covering United Parcel Service, Inc. (UPS)

Among 22 analysts covering United Parcel Service (NYSE:UPS), 8 have Buy rating, 1 Sell and 13 Hold. Therefore 36% are positive. United Parcel Service had 57 analyst reports since July 29, 2015 according to SRatingsIntel. BMO Capital Markets maintained United Parcel Service, Inc. (NYSE:UPS) rating on Wednesday, July 5. BMO Capital Markets has “Hold” rating and $11500 target. Robert W. Baird maintained the stock with “Hold” rating in Friday, September 29 report. Zacks upgraded United Parcel Service, Inc. (NYSE:UPS) rating on Tuesday, September 1. Zacks has “Hold” rating and $110 target. Citigroup upgraded the shares of UPS in report on Tuesday, August 8 to “Buy” rating. The company was maintained on Thursday, January 18 by Stifel Nicolaus. The stock has “Market Perform” rating by Cowen & Co on Friday, April 29. The company was upgraded on Monday, December 4 by Deutsche Bank. The stock has “Hold” rating by Deutsche Bank on Wednesday, November 2. S&P Research maintained the stock with “Buy” rating in Tuesday, September 22 report. The rating was maintained by Oppenheimer with “Outperform” on Wednesday, February 3. See United Parcel Service, Inc. (NYSE:UPS) latest ratings:

18/01/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $122.0 Maintain
17/01/2018 Broker: Susquehanna Rating: Hold New Target: $147.0 Maintain
08/01/2018 Broker: Stephens Rating: Hold New Target: $147.0 Maintain
08/01/2018 Broker: Deutsche Bank Rating: Buy New Target: $145.0 Maintain
11/12/2017 Broker: Morgan Stanley Rating: Sell New Target: $79.0 Maintain
04/12/2017 Broker: Deutsche Bank Old Rating: Hold New Rating: Buy Upgrade
30/11/2017 Broker: BMO Capital Markets Rating: Hold New Target: $130.0 Maintain
13/11/2017 Broker: Goldman Sachs Rating: Buy New Target: $148 Initiates Coverage On
27/10/2017 Broker: UBS Rating: Neutral Old Target: $117 New Target: $126 Maintain
27/10/2017 Broker: Loop Capital Rating: Hold Old Target: $120 New Target: $128 Maintain

Recently, a huge insider trading sale was made. Isaac Ciechanover, the Chief Executive Officer and an insider of Atara Biotherapeutics Inc unloaded precisely 19,300 shares of Atara Biotherapeutics Inc, worth close to $680,534 USD, at $35.3 of a share at the time of the sale. In the last 30 days, he also unloaded 100,000 shares valued at $2,715,308 USD. Isaac finished this sale on January 29, 2018. The Form 4 is free at your disposal here at the Washington-based Security and Exchange Commission website. This is a major stocks unloading, and one that is unlikely to remain a secret, as it decreased his ownership of Atara Biotherapeutics Inc to 2.75% total market cap, for a total of 1.04 million shares.

Investors sentiment increased to 1.14 in Q3 2017. Its up 0.09, from 1.05 in 2017Q2. It improved, as 46 investors sold United Parcel Service, Inc. shares while 390 reduced holdings. 104 funds opened positions while 395 raised stakes. 451.38 million shares or 0.77% more from 447.95 million shares in 2017Q2 were reported. Veritas Investment (Uk) stated it has 650 shares or 0.03% of all its holdings. Professional Advisory Svcs Incorporated has invested 3.64% in United Parcel Service, Inc. (NYSE:UPS). Silvercrest Asset Gp Ltd Liability owns 22,680 shares. Marco Investment Mgmt Llc reported 136,829 shares. Pecaut stated it has 17,550 shares or 1.72% of all its holdings. Sky Inv Gp Limited Liability Corp stated it has 1.84% of its portfolio in United Parcel Service, Inc. (NYSE:UPS). Ls Advsr Ltd Liability Com owns 0.17% invested in United Parcel Service, Inc. (NYSE:UPS) for 24,265 shares. Ironwood Inv Counsel Ltd reported 1.86% in United Parcel Service, Inc. (NYSE:UPS). Lowe Brockenbrough And holds 0.23% or 12,223 shares. 29,583 are held by Gam Hldgs Ag. Nippon Life Insurance accumulated 20,549 shares or 0.05% of the stock. Baker Boyer Savings Bank owns 2,375 shares or 0.94% of their US portfolio. Fulton Savings Bank Na reported 0.11% of its portfolio in United Parcel Service, Inc. (NYSE:UPS). Buckhead Capital Ltd Liability Corp invested in 0.13% or 4,930 shares. Sns Financial Grp Incorporated Ltd Liability Corp owns 4,217 shares.

Since August 22, 2017, it had 0 insider purchases, and 1 sale for $2.02 million activity. 17,699 shares valued at $2.02M were sold by Gershenhorn Alan on Tuesday, August 22.

United Parcel Service, Inc., a package delivery company, provides transportation, logistics, and financial services in the United States and internationally. The company has market cap of $112.58 billion. It operates in three divisions: U.S. It has a 32.16 P/E ratio. Domestic Package, International Package, and Supply Chain & Freight.

The stock decreased 1.57% or $2.08 during the last trading session, reaching $130.64. About 2.75M shares traded. United Parcel Service, Inc. (NYSE:UPS) has risen 2.10% since January 30, 2017 and is uptrending. It has underperformed by 14.60% the S&P500.

Among 7 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Atara Biotherapeutics has $80 highest and $8 lowest target. $27.60’s average target is -25.91% below currents $37.25 stock price. Atara Biotherapeutics had 19 analyst reports since September 9, 2015 according to SRatingsIntel. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Outperform” rating given on Friday, October 9 by William Blair. Goldman Sachs initiated it with “Neutral” rating and $38 target in Wednesday, November 18 report. The firm has “Sell” rating by Citigroup given on Tuesday, December 15. Citigroup maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) rating on Friday, August 19. Citigroup has “Sell” rating and $8 target. The stock has “Sell” rating by Goldman Sachs on Thursday, September 15. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. Jefferies maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) rating on Thursday, August 31. Jefferies has “Buy” rating and $30.0 target. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Neutral” rating given on Wednesday, January 3 by Citigroup. JMP Securities maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Tuesday, December 15 with “Market Outperform” rating. The stock has “Buy” rating by Canaccord Genuity on Wednesday, September 9.

Since August 10, 2017, it had 0 buys, and 18 selling transactions for $4.21 million activity. $91,800 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was sold by Haqq Christopher on Friday, September 15. The insider Ciechanover Isaac E. sold 4,400 shares worth $66,066. 1,184 shares were sold by Gallagher Carol Giltner, worth $16,931 on Tuesday, August 15. The insider Clark Mitchall G. sold 3,021 shares worth $43,291. 9,464 Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares with value of $140,802 were sold by Soffer Gad. 37,000 shares were sold by MCGRATH JOHN, worth $900,815 on Thursday, January 11.

Analysts await Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to report earnings on March, 8. They expect $-1.14 EPS, down 80.95% or $0.51 from last year’s $-0.63 per share. After $-1.02 actual EPS reported by Atara Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.76% negative EPS growth.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $1.40 billion. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.

Investors sentiment increased to 1.54 in 2017 Q3. Its up 0.26, from 1.28 in 2017Q2. It improved, as 8 investors sold Atara Biotherapeutics, Inc. shares while 16 reduced holdings. 9 funds opened positions while 28 raised stakes. 26.16 million shares or 3.51% more from 25.27 million shares in 2017Q2 were reported. 12 West Cap Lp holds 398,700 shares. Northern Trust Corp has 286,973 shares. Wells Fargo & Mn holds 55,151 shares or 0% of its portfolio. Perceptive Advsrs Llc has invested 0.02% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Swiss Bank owns 28,600 shares or 0% of their US portfolio. Washington-based Parametric Portfolio Assoc Llc has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Arrowmark Colorado Limited Liability Corp holds 2.78 million shares or 0.52% of its portfolio. Envestnet Asset Mgmt has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 1,454 shares. Voya Inv Ltd Llc invested in 0% or 11,813 shares. Blackrock invested 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Deutsche Bankshares Ag has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Dekabank Deutsche Girozentrale has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Rhumbline Advisers invested 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Morgan Stanley owns 1.44 million shares. California State Teachers Retirement System has 40,323 shares.

It closed at $37.25 lastly. It is up 7.28% since January 30, 2017 and is downtrending. It has underperformed by 23.98% the S&P500.